Second Line Trials

1. A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)

      ClinicalTrials.gov Identifier:             NCT02538666      

This study is active but not currently recruiting. 

The purpose of this study is to show that maintenance therapy with nivolumab, or nivolumab plus ipilimumab followed by nivolumab alone, will prolong Overall Survival and Progression Free Survival compared with placebo in subjects with extensive stage disease small cell lung cancer who have completed first line chemotherapy.

Alberta
Local Institution
Edmonton, Alberta, Canada, T6G 1Z2

New Brunswick 
Local Institution
Moncton, New Brunswick, Canada, E1C 6Z8
 
Ontario
Local Institution
Oshawa, Ontario, Canada, L1G 2B9
 
Local Institution
Sudbury, Ontario, Canada, P3E 5J1
 
Local Institution
Windsor, Ontario, Canada, N8W 2X3

2. A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)

      ClinicalTrials.gov Identifier:             NCT02066636      

This study is active but not currently recruiting. 
 
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen.

Quebec
Local Institution
Levis, Quebec, Canada, G6V 3Z1
 
Local Institution
Montreal, Quebec, Canada, H3T 1E2

Ontario
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
 
Local Institution
Ottawa, Ontario, Canada, K1H 8L6
 
Local Institution
Toronto, Ontario, Canada, M5G 2M9

Nova Scotia
Local Institution
Halifax, Nova Scotia, Canada, B3H 2Y9

Alberta
Local Institution
Calgary, Alberta, Canada, T2N 4N2
3. Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell lung Cancer Patients
      ClinicalTrials.gov Identifier:             NCT02879760      

This study is active but not currently recruiting. 

This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with an platinum based chemotherapy.

Ontario 
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 5C2
 
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
 
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
 
University Health Network
Toronto, Ontario, Canada, M5G 2M9

New Brunswick
Moncton Hospital
Moncton, New Brunswick, Canada, E1C 6Z8
 
Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2

4. Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001)

      ClinicalTrials.gov Identifier:             NCT02733250      

This study is active but not currently recuruiting. 
 
The purpose of this study is to determine the optimal dose of nab-paclitaxel to be safely administered in combination with pembrolizumab in patients with advanced inoperable non-small cell lung cancer. The study is also aimed at evaluating the efficacy of the combination therapy.

Quebec
Centre hospitalier de l'université de Montréal (CHUM) - Notre-Dame Hospital
Montreal, H2L 4M1
 
Jewish General Hospital
Montreal,  H3T 1E2

5. Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

      ClinicalTrials.gov Identifier:             NCT02785952      

This study is active but not currently recruiting. 

This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a "non-match" sub-study that includes all screened patients not eligible for a biomarker-driven sub-study. Monoclonal antibodies, such as nivolumab and ipilimumab, may be able to shrink tumours. It is not yet known whether nivolumab works better with or without ipilimumab in treating patients with squamous cell lung cancer.

Ontario
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
 
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, Canada, K1H 8L6
 
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9

Saskatchewan
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
 
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada, S7N 4H4

Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2

6. ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients (ALTA-1L)

      ClinicalTrials.gov Identifier:             NCT02737501      

This study is active but not currently recruiting. 

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in ALK-positive Advanced Lung Cancer Patients.

Ontario 
Princess Margaret Cancer Centre (Site #083)
Toronto, Ontario, Canada, MG5 2M9

7. Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

      ClinicalTrials.gov Identifier:             NCT03539536      

This study is currently recruiting participants. 

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).

Alberta 
Cross Cancer Institute / ID# 204540                          Recruiting
Edmonton, Alberta, Canada, T6G 1Z2

Ontario
The Ottawa Hospital / ID# 205579                            Recruiting 
Ottawa, Ontario, Canada, K1H 8L6 

Princess Margaret Cancer Centre / ID# 204423        Recruiting 
Toronto, Ontario, Canada, M5G 2M9 

Quebec 
CISSS de la Monteregie / ID# 211356                       Recruiting 
Greenfield Park, Quebec, Canada, J4V 2H1 

8. Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy. (HUDSON)

      ClinicalTrials.gov Identifier:             NCT03334617      

This study is currently recruiting participants.

This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

Alberta
Research Site                                                    Recruiting
Edmonton, Alberta, Canada, T6G 1Z2

Ontario
Research Site                                                    Suspended                       
Brampton, Ontario, Canada, L2P 2V3               

Research Site                                                    Recruiting
Ottawa, Ontario, Canada, K1H 8L6                   

Research Site                                                    Recruiting        
Toronto, Ontario, Canada, M5G 2M9 
             
Quebec
Research Site                                                    Recruiting
Montreal, Quebec, Canada, H2X 3E4 

            9. Phase III Study Evaluating Efficacy
and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)

      ClinicalTrials.gov Identifier:             NCT03626545      

This study is active but not currently recruiting.

This phase III study is designed to evaluate the role of IL-1β inhibition in combination with docetaxel in subjects with advanced NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy. The randomized III part will be preceded by a safety run-in part in which the recommended dose of the combination of canakinumab and docetaxel will be confirmed.

British Columbia 
Norvartis Investigative Site                                             
Vancouver, British Columbia, Canada, V5Z 4E6 

Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H4A 3J1

10. Phase 2 Study of Tarloxotinib in Patients With NSCLC Harboring EGFR Exon 20 Insertion or HER2-activating Mutations (RAIN)

      ClinicalTrials.gov Identifier:              NCT03805841      

This study is currently recruiting participants. 

A Phase 2 Study to Evaluate the Objective Response to Tarloxotinib Administered Intravenously to Patients With Non Small Cell Lung Cancer That Harbors Either EGFR Exon 20 Insertion or a HER2-Activating Mutation.

Ontario
RAIN-701 Study Site                                                Recruiting 
Toronto, Ontario, Canada, M5G 2C1 
Contact: Natalia Ramnarine, +1 416-581-7603 
Natalia.Ramnarine@uhn.ca
Principal Investigator: Adrian Sacher, MD